Mirum plans FDA submission for hepatitis D treatment as competition brews
Mirum’s hepatitis D treatment has succeeded in the second of two pivotal trials. Now comes the next challenge: competing with rivals in a growing market. The Phase 3 trial, called AZURE-4, enrolled 113 treatment-naïve patients ...
Chris Peetz, Mirum Pharmaceuticals CEO November 10, 2026 02:31 PM EST R&DPharma Mirum plans FDA submission for hepatitis D treatment as competition brews Nicole DeFeudis Senior Reporter Mirum’s hepatitis D treatment has succeeded in the second of two pivotal trials. Now comes the next challenge: competing with rivals in a growing market. … Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that